PPCBHIGH SIGNALFINANCIAL10-K

PPCB experienced massive dilution with outstanding shares dropping from 688M to 12.8M while operating losses exploded from -$1.5M to -$57.3M, despite a dramatic improvement in balance sheet strength.

The extreme reduction in share count (98% decrease) alongside massive operating loss expansion suggests either a reverse stock split or major restructuring event that wasn't clearly disclosed in the language changes. The simultaneous balance sheet improvement indicates possible new financing or asset revaluation, but the operational deterioration raises serious questions about business sustainability.

Comparing 2025-09-29 vs 2024-09-30View on EDGAR →
FINANCIAL ANALYSIS

PPCB's financials show a paradoxical situation where the balance sheet strengthened dramatically (current assets up 32,732% to $8.4M, stockholders' equity swinging from -$3.8M to +$13.9M) while operational performance collapsed catastrophically (operating losses increased 36x to -$57.3M, net losses up 31x to -$58.9M). The 98% reduction in outstanding shares from 688M to 12.8M suggests a major corporate action like a reverse split, while operating cash flow improved modestly despite the operational losses. This combination of balance sheet strength, operational weakness, and extreme share count changes signals significant corporate restructuring with unclear implications for shareholder value.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
+32732.1%
$25K$8.4M

Current assets grew 32732.1% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+27028.9%
$72K$19.6M

Asset base grew 27028.9% — expansion through organic growth, acquisitions, or capital deployment.

Operating Income
P&L
-3628.9%
-$1.5M-$57.3M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-3136.6%
-$1.8M-$58.9M

Net income declined 3136.6% — review whether driven by operations, interest costs, or non-recurring items.

Stockholders Equity
Balance Sheet
+468%
-$3.8M$13.9M

Equity base grew 468% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
+80.4%
$2K$4K

Cash position surged 80.4% — strong cash generation or capital raise providing significant financial cushion.

Capital Expenditure
Cash Flow
-70.9%
$10K$3K

Capex reduced 70.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+56.7%
-$935K-$405K

Operating cash flow surged 56.7% — exceptional cash generation, highest quality earnings signal.

Total Liabilities
Balance Sheet
+48.7%
$3.9M$5.7M

Liabilities grew 48.7% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Liabilities
Balance Sheet
+47.1%
$3.8M$5.6M

Current liabilities surged 47.1% — significant near-term obligations; verify ability to meet short-term debt.

LANGUAGE CHANGES
NEW — 2025-09-29
PRIOR — 2024-09-30
ADDED
on December 31, 2024 (which was $0.0004 per share), based on 869,738,031 shares of common stock, par value $0.001 per share ( Common Stock ) outstanding on such date.
As of September 24, 2025, there were 12,806,747 shares of Common Stock issued and outstanding.
We entered into a second two-year joint research and collaboration agreement with the University of Ja n, which concluded successfully late 2024.
A third agreement is planned for the next three years for future joint drug discovery research activities designed to produce a new compound which enhances the anti-cancer effects of proenzymes and consequently introduces a new therapeutic drug class for the treatment and prevention of metastatic cancer.
Studies reveal the genetic changes in cells that cause cancer and spur its growth.
+7 more — sign up free →
REMOVED
on December 29, 2023 (which was $0.012 per share), based on 36,169,023 shares of common stock, par value $0.001 per share ( Common Stock ) outstanding on such date.
As of September 25, 2024, there were 688,022,017 shares of Common Stock issued and outstanding.
We entered into a second two-year joint research and collaboration agreement with the University of Ja n, which is undertaking the research activities for the POP1 Program.
Studies are revealing the genetic changes in cells that cause cancer and spur its growth.
We received a refund of $196,937 AUD ($129,132) and $192,872 AUD ($129,841) for the years ended June 30, 2024 and 2023, respectively.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →